New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:26 EDTPCYC, INCYNomura is a buyer of Incyte and Pharmacyclics into ASCO meetings
Nomura is a buyer of Incyte (INCY) and Pharmacyclics (PCYC) following the ASCO abstract releases. The firm expects 50mg dose data on June 2 to meet investor expectations and for shares to recover. For Pharmacyclics, the analyst expects investor focus to be on negativity rates of Phase I/II trial of competitor ABT-199 + Rituxan and Imbruvica RESONATE Phase III data on June 3.
News For INCY;PCYC From The Last 14 Days
Check below for free stories on INCY;PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for INCY;PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use